Aisling Capital Management as of June 30, 2023
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 16 positions in its portfolio as reported in the June 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 51.1 | $104M | 6.1M | 17.20 | |
| Verona Pharma Sponsored Ads (VRNA) | 11.6 | $24M | 1.1M | 21.14 | |
| Syndax Pharmaceuticals (SNDX) | 10.5 | $22M | 1.0M | 20.93 | |
| Biomea Fusion (BMEA) | 8.6 | $18M | 799k | 21.95 | |
| Monte Rosa Therapeutics (GLUE) | 4.9 | $10M | 1.5M | 6.85 | |
| Reneo Pharmaceuticals (RPHM) | 2.8 | $5.8M | 886k | 6.56 | |
| Nuvation Bio Com Cl A (NUVB) | 2.2 | $4.6M | 2.5M | 1.80 | |
| Aclaris Therapeutics (ACRS) | 2.2 | $4.5M | 435k | 10.37 | |
| Elevation Oncology (ELEV) | 2.1 | $4.3M | 2.8M | 1.52 | |
| Spruce Biosciences (SPRB) | 1.3 | $2.6M | 1.2M | 2.15 | |
| Poseida Therapeutics I (PSTX) | 0.9 | $1.8M | 1.0M | 1.76 | |
| Marker Therapeutics (MRKR) | 0.5 | $974k | 314k | 3.10 | |
| Avrobio Ord (AVRO) | 0.5 | $959k | 1.0M | 0.95 | |
| Aeglea Biotherapeutics | 0.4 | $762k | 1.7M | 0.45 | |
| Viracta Therapeutics (VIRX) | 0.2 | $407k | 289k | 1.41 | |
| Atreca Cl A Com (BCEL) | 0.2 | $380k | 388k | 0.98 |
